Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | WDR5 | P61964 | 3/20 | 0.41 |
| ▸ | EDNRB | P24530 | 2/20 | 0.41 |
| ▸ | EDNRA | P25101 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24333691 | 1.00 | TSHR (0.52) | TSHRSMN1; SMN2GLAGAAALOX15 | |
| SCHEMBL10642047 | 0.84 | GAA (0.54) | TSHRSMN1; SMN2GAAHTTLMNA | |
| SCHEMBL10642042 | 0.84 | GAA (0.54) | TSHRSMN1; SMN2GAAHTTLMNA | |
| SCHEMBL10641825 | 0.83 | ALDH1A1 (0.48) | TSHRSMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL10641829 | 0.83 | ALDH1A1 (0.48) | TSHRSMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL10641950 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2GAAALDH1A1HTTLMNA | |
| SCHEMBL10641953 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2GAAALDH1A1HTTLMNA | |
| SCHEMBL10641606 | 0.81 | ALPL (0.44) | TSHRSMN1; SMN2GLAGAAHTT | |
| SCHEMBL10641655 | 0.81 | ALDH1A1 (0.51) | TSHRSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL10641651 | 0.81 | ALDH1A1 (0.51) | TSHRSMN1; SMN2GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | TSHR 1710/4885SMN1; SMN2 3314/4885GLA 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.